- Intellectual Property (38)
- Healthcare (19)
- Company/Commercial (18)
- Information Technology (13)
- Litigation / Dispute Resolution (13)
- Corporate (11)
- Regulatory and compliance (9)
- Banking / Finance (6)
- Funds (6)
- Media/Entertainment/Sport (6)
- Licensing/Gaming/Betting (4)
- Real Estate (4)
- Telecoms (4)
- Employment (3)
- Insolvency & restructuring (3)
- Competition/EU (2)
- Planning (2)
- Tax (2)
- Commodities (1)
- Construction (1)
- Energy (1)
- Environment (1)
- Financial services (1)
- Private Client (1)
- Transport (Including aviation and shipping) (1)
Sort By: Newest first | Oldest first
The MHRA offers useful guidance on the difference between apps that are regulated as medical devices and those that are related to healthcare but do not qualify.
At a time when well-known names are disappearing from the high street as a result of retailers going into administration, the spectre of corporate insolvencies has never loomed larger.
Edward Cooper and Jill Carey discuss how businesses can avoid certain pitfalls when renewing a commercial lease.
Ian McEwan and Jill Carey provide a summary of the issues that should be taken into account by a company when planning an exit strategy.
Fundraisings of early-stage life science companies can be complicated affairs from the point of view of actually securing the funds from investors in the first place.
The articles of association are a contract between the company and each shareholder and between the shareholders themselves.
A life sciences company raises funds either by issuing shares or by borrowing money from individuals, venture capital bodies or lending institutions.
Two new references have been made to the CJEU asking for preliminary rulings on issues under Regulation (EC) No 469/2009.
A number of life sciences industry bodies have jointly published a report entitled ‘From vision to action: delivery of the strategy for UK life sciences’.
It is common in investments for life sciences companies for a term sheet to be put in place between the investors and the founders that sets out the key terms of the investment.
This case relates to an application for payment of damages, further to a cross-undertaking on a preliminary injunction.
One innovative deal structure is geographical licensing. While apparently simple on the face of it, the devil is in the detail.
The latter half of 2013 proved to be an interesting period for the pharmaceutical sector from a competition law perspective.
Taylor Wessing has launched its third Cambridge newsletter, providing legal news and updates for companies in Cambridge and the surrounding areas.
After four years of waiting, the Food and Drug Administration has released its draft social media guidance.
The first preliminary injunction decision in Germany relating to a ‘bio-better’ type drug has been made in Amgen v Teva in the Düsseldorf District Court.
This unusual application related to proceedings to revoke a European patent and a declaration that an SPC based upon it would not be valid.
The CJEU delivered three important rulings on the application of the supplementary protection certificate regulation 469/2009/EC on the same day.
In the life sciences industry, highly skilled people are employed in the research and development of drug candidates and other advancements associated with therapy.
A Düsseldorf court has referred questions to the CJEU on the supply of substances by a third party to a company that intends to use the substance for obtaining a marketing authorisation.